

Species Sensitivities and Prediction of Teratogenic Potential

by James L. Schardein,* Bernard A. Schwetz,† and Michael F. Kenel*

Many chemicals shown to be teratogenic in laboratory animals are not known to be teratogenic in humans. However, it remains to be determined if the unresponsiveness of humans is due to lessened sensitivity, to generally subteratogenic exposure levels, or to the lack of an appropriate means of identifying human teratogens. On the other hand, with the exception of the coumarin anticoagulant drugs, those agents well accepted as human teratogens have been shown to be teratogenic in one or more laboratory species. Yet, no single species has clearly distinguished itself as being more advantageous in the detection of human teratogens over any other. Among the species used for testing, the rat and mouse most successfully model the human reaction, but the rabbit is less likely than other species to give a false positive finding. Among species less commonly used for testing, primates offered a higher level of predicability than others. Regarding concordance of target malformations, the mouse and rat produced the greatest number of concordant defects, but they also were responsible for the most nonconcordant responses as well. Since no other species is clearly more predictive of the human response, it is concluded that safety decisions should be based on all reproductive and developmental toxicity data in light of the agent's known pharmacokinetic, metabolic and toxicologic parameters.

Introduction

The extrapolation of animal data to the human is the foundation of safety evaluation of chemicals and drugs prior to human exposure. As will be shown, there is at present no perfectly suitable animal model from which to make these extrapolations in most cases, nor is it abundantly clear just what endpoints residing in the animal database are most important in this determination. In short, it is conceded that the predictive value of animal teratogenicity tests in extrapolating results into terms of human safety is imperfect. Consider the fact that of over 2800 chemicals now reported to have been assayed in animals for teratogenic potential, only about 14 chemicals or groups of chemicals have been shown to have this propensity in humans (1). Put another way, there are about 1000 or so chemicals that demonstrate some measure of teratogenicity in animals but for which we have no evidence at all that they share this property in humans. However, this discrepancy may only reflect that we cannot clearly recognize ter-

atogenicity in humans. It should be realized from the onset that testing strategies of drugs for teratogenic potential on the one hand need to be clearly distinguished from testing of industrial or environmental chemicals on the other. Conditions of exposure, numbers of potential victims of exposure, benefit considerations, economics and other factors are radically different in the two cases and affect both the philosophy of testing and the acceptable risk (2).

Fortunate as we are that newly identifiable human teratogens have not wreaked havoc in the same manner as in the 10,000 thalidomide victims in 1961 to 1962, or in the 20,000 rubella-infected children in 1964, correlations of animal and human responses may not be providing us with the necessary answers to avoid potentially similar situations in the future. It is the apparent lack of association that precludes accurate prediction of teratogenic potential in extrapolating from animals to humans. We are really left at present with the dilemma of not being capable of selecting which animal species are the most predictive of the likely human response.

Two decades ago, with the thalidomide catastrophe, the rabbit emerged as the sensitive species with respect to this teratogen, highlighted in part because of the negative and/or inconclusive results produced in a large number of other laboratory species tested at the time.

*International Research and Development Corporation, Mattawan, MI 49071.

†National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709.

Enthusiasm for wider use of primates ensued soon thereafter, chiefly on taxonomic grounds, but also due to confirmatory results produced with thalidomide and our inexperience in what to look for in an animal model to predict teratogenicity. With the subsequent demonstration that even subhuman primates did not respond positively to several other suspected human teratogens, the fact remains that the human female is the only truly reliable model. However, a number of reasons obviate against direct testing. Since the mid and late 1960s, then, virtually every species maintained in the laboratory (and some that were normally not!) has been touted as a potential teratogenic model.

A number of factors relate to the inability to predict accurately and the impreciseness in extrapolating from one species to another, and include genetic heterogeneity (affecting absorption, metabolism and excretion of a given chemical), and variability in diet, size, developmental patterns, intercurrent disease processes, placental transfer, etc. It seems likely that variations in metabolic pathways are a major cause of species differences (3).

The traditional endpoint in assessing teratogenic potential is outright structural malformation. A given chemical may, however, kill fetuses rather than malform them at a given dose in one species, whereas it may result in deformation among survivors at the same dosage in another species. Further, the use of other endpoints representing developmental toxicity, e.g., mortality or effects on growth or function, may be just as appropriate as inducing terata in several regards (see below). Perhaps better correlation between laboratory and the human species might be attained through collection and analysis of all feasible developmental toxicity endpoints. The purpose of this presentation therefore, is to re-evaluate the species selection process in light of the plethora of information gathered on the potential developmental toxicity and sensitivities of species to therapeutic agents and environmental chemicals.

Historical Perspective

A laboratory animal to be used in evaluating human teratogenic risk ideally would be chosen because it metabolizes and distributes a given chemical and transfers it across the placenta in similar ways to man (4). Unfortunately, response to a given chemical by a particular species of animal is almost as variable as the number of chemicals tested.

Despite a wide range of species having been used in teratology studies (2,5-8), no one species has been clearly demonstrated to everyone's satisfaction to be the one of choice to the exclusion of all others. This is particularly true with regard to the few proven human teratogens, as will be amply demonstrated below. It need only be recalled that the marked teratogenicity of thalidomide in man has been observed in relatively few species. Although some nine subhuman primate species

have demonstrated the characteristic limb defects observed in humans when administered that drug, only 8 of 15 other putative human teratogens have been teratogenic in one or more of the various primate species (8).

Rodents are frequently used in teratogenicity studies. While the laboratory rat has been the most frequently used rodent species, the susceptibility of this species to putative teratogens has been variable, and certain teratogens such as cortisone (4,9), thalidomide (5,6), trimethadione (10), and lithium carbonate (11) have elicited a poor teratogenic response. Mice have also been used frequently in teratology studies despite the marked variability of responses observed with different strains (12-14). Differences in intraspecies sensitivity has also been reported for phenytoin (15) and ethanol (16,17). Furthermore, stress-induced enhancement of already comparatively high plasma corticosterone levels is believed to be the underlying mechanism facilitating stress-related teratogenicity observed in the mouse (18,19). Therefore, the mouse would seem unsuitable for the testing of such agents as sedatives, tranquilizers, hypnotics or agents requiring unusual, manipulative procedures. The rat and rabbit are less prone to stress-induced teratogenicity (20,21). A lack of steroid-induced cleft palates in man led Tuchmann-Duplessis (6) to conclude that the unique susceptibilities encountered with various mouse strains may lead to many false positives. However, it can be said that inbred mouse strains are probably more valid indicators than outbred strains in assessing teratogenic potential (13).

Recently it has been suggested that hamsters may serve as an appropriate rodent species for teratogenicity testing (22). A lack of data on spontaneous malformations and intraspecies differences (23), while offering no distinct advantage over more commonly used rodent species (6), would tend to limit the usefulness of this species. To date, only Canada includes hamsters as a preferred animal of choice in teratogenicity testing for regulatory decisions.

The guinea pig has also been suggested as an appropriate rodent species (24,25). Described as having a reproductive endocrinology more closely related to man than other rodents, limitations of a 68-day gestation period, dependence upon an everted yolk sac, and lack of data concerning intraspecies differences may preclude the common use of this species for teratogenicity testing.

Rabbits have been used routinely as the nonrodent species required by most regulatory agencies. As in the case with rats and mice, the selection of this species has been based largely on availability, economy, and long history as a laboratory animal. While the rabbit's responsiveness to thalidomide has supported its appropriateness as a test species (26), it has not been responsive to such putative human teratogens as alcohol (27) and lithium carbonate (11). In addition, this species has limited use in the testing of antibiotics as induced imbalances in the digestive microflora has led to ma-

ternal malnutrition, increased embryoletality and fetal hypoplastic skeletal development (28).

It has been suggested that the ferret may serve as an alternative to rabbits as the nonrodent species of choice (29–32). Special problems of diet, seasonal breeding, length of gestation (42 days), and insufficient historical data may preclude the widespread use of this species. However, unlike rodents and rabbits, but similar to man, the ferret embryo is not maintained by an everted yolk sac placenta. Therefore, this species may have merit in the teratogenic screening of compounds whose mechanism of action involves the placenta (29). The species has also been singled out as especially valuable in assessing behavior in the context of reproductive toxicology (33).

Swine (34,35), dogs (34,36,37) and cats (5,38) have been suggested as possible nonrodent species of choice. All three species have been only variably responsive to the teratogenicity of thalidomide. Further, limitations of space, seasonal estrus, prolonged gestation, differences in xenobiotic metabolism, susceptibility to underlying disease, and inadequate control data have reserved the choice of these species for those occasions when more conventional laboratory animals leave unanswered questions.

Various species of primates have been suggested as animals of possible selection for teratogenicity testing (4,39–44). It must be emphasized that the close parallel between man and monkey with regard to the teratogenicity of thalidomide, norethindrone, testosterone, diethylstilbestrol, and methylmercury (44) has not been demonstrated for other chemicals which are teratogenic in humans. In particular, methotrexate has been shown to be teratogenic in man and rat, but macaque and rhesus monkeys were refractory at doses equivalent to or considerably higher than those above the usual human dose (46). Similarly, attempts to duplicate in monkeys the aminopterin teratogenicity observed in man showed monkeys more susceptible to embryoletality than malformation (47). On this basis, as well as the limitations due to scarcity of these animals, it has been suggested they not be used for widespread teratogenicity screening, but rather reserved for cases of questionable results from more commonly used laboratory animals or in toxicological evaluation of a very few selected agents (6,47,48).

Despite a lack of agreement as to the most appropriate animal model, a general consensus exists as to the necessary criteria for the selection of such a model. It is generally accepted by scientists and officials responsible for safety evaluation that, for realistic testing, the maternal–placental–embryonic relationship as characterized in mammals is essential. In addition, metabolic rates as well as the pathways of xenobiotic metabolism should be comparable to those of man. Parent compounds and their respective intermediates should undergo distribution, including transplacental crossing, in a manner similar to that in human beings. Also, the patterns of embryonic and fetal structural and metabolic

development should parallel those in man. Finally, the ideal animal model should be able to be easily bred, have a short gestation, produce large litters, and be economically housed and easily handled.

While it would be accepted at face value by all that extrapolation to humans should be made from the most sensitive animal species tested, the confidence in such an extrapolation is increased as the number of species tested increases, as will be discussed later. When different results are obtained from different species, it is important to determine which of the test species more closely resembles humans for the relevant underlying mechanisms (49).

Since no single species thus far evaluated fulfills all of the above criteria, the best compromise would appear to be the selection of two or more species. This approach has been recommended by others recently (50). As mentioned, past choices by scientists and regulatory officials alike, have often been arbitrary, based solely on past experiences and the availability of the test species.

Species Selection by Regulatory Agencies

Without exception, principal regulatory agencies throughout the world require the use of two species to assess the teratogenic potential of drugs and chemicals (Table 1). While tacit approval is given by several agencies for the use of less common species, the requirement in general mandates the use of one nonrodent and presumably, one rodent species. For all intents and purposes, this is meant to imply the rat and rabbit. Although the U.S. Food and Drug Administration (FDA) regulations state that the mouse and rabbit have occasionally been preferable to the rat, rarely in practice has the mouse substituted for the rat. As with other regulatory agencies, the selection of a species other than the mouse, rat or rabbit has most often been reserved for those cases of equivocal results from more conventionally used species. The World Health Organization lists perhaps the broadest range of acceptable alternatives, including: hamsters, guinea pigs, ferrets, cats, pigs, dogs and non-human primates, while the U.S. Environmental Protection Agency (EPA) allows for the selection of a nonconventional laboratory species if an appropriate rationale is given. Presumably such a rationale would be based on similarities in xenobiotic metabolism, pharmacokinetics, etc. However, in acknowledging the usual lack of such data, regulatory agencies often recommend a species that is easy to use and characterized for its response to known teratogens. The same stipulations generally exist for other national regulatory agencies, including those of Australia, West Germany, Spain, Argentina, Austria, Denmark, Finland, France, Ireland, Italy, and Sweden. Paradoxically, one country, Norway, requires the use of one species in which the effect of thalidomide has been documented (presumably rabbit or primate) in addition to either rat or mouse.

Table 1. Species requirements according to selected governmental regulations guidelines.

Government	Agency	Species selection	Comments	Reference
U.S.A.	FDA (drugs)	At least two species. Most frequently used have been the mouse, rat, and rabbit. Mouse and rabbit have occasionally been preferable to the rat. Experience in monkeys and other species limited, but encouraged.	Although metabolism and trans-placental passage mentioned important for the selection of an animal model for entire reproduction studies, not specifically mentioned as essential to teratology evaluation.	(51)
	FDA (additives)	Species commonly used are the rat, mouse, hamster, and rabbit. Preference given to rat and rabbit.	Common laboratory strains are to be used. The strain should not have low fecundity and should be characterized for its response to teratogens.	(52)
	EPA (pesticides)	At least two mammalian species, preferably rat and rabbit. Allows for selection of different species if rationale appropriate.	Commonly used strains should be employed. Strain should not have low fecundity and should be characterized for its response to teratogens.	(53)
Canada	Pesticides Division of Agriculture Canada	Two species are to be chosen from rat, mouse, hamster, and rabbit		(54)
	Bureau of Human Prescription Drugs	Should be conducted on two species. Frequently used have been mouse, rat, and rabbit. One should be a nonrodent (rabbits are acceptable). With uninterpretable results a third species should be chosen.	Sometimes it is useful to compare the pharmacokinetics of a drug in nonpregnant and pregnant animals to determine maternal-fetal distribution of drugs.	(55)
United Kingdom	Committee of Safety of Medicines (drugs)	In two animal species, one a nonrodent. Third species other than rodent or lagomorph if results uninterpretable.	Suggest tests to see if pharmacokinetics differ in pregnant and nonpregnant animals.	(56)
Japan	Ministry of Health and Welfare (drugs)	At least one species of rodent, such as rats or mice, and one of nonrodent, such as rabbits, should be used.	Prefer mammals of similar metabolism to man. However, if unknown use a species and strain easy to employ, characterized for its response to teratogens, and having a low background of deformities.	(57)
	Ministry of Agriculture and Forestry (pesticides)	Sufficient number of more than one kind of experimental animal such as mice and rats are to be used.		(65)
Europe (common market)	OECD (chemicals)	Commonly used are the rat, mouse, hamster, and rabbit. Preferable are the rat and rabbit.	Use a common strain not of low fecundity and characterized for its response to teratogens.	(59)
Worldwide	WHO (drugs)	No recommendation as to acceptable species. However, should use two species, one a nonrodent, if possible.	Frequently used are mouse, rat, and rabbit. However, the use of hamsters, guinea pigs, ferrets, cats, pigs, dogs, and non-human primates is encouraged.	(60)

The reason for the apparent restriction to rat and rabbit is probably twofold. First, these species have the greatest historical control database available. In this light, Japanese requirements further suggest that the

species of choice should have a low background of deformities. It is well known that intraspecies differences in background malformation rates are not only more consistent but significantly less in rats and rabbits than

Table 2. Discovery and method of ascertainment of human teratogens.

Teratogen	Teratogenic: initial discovery (species)	Probable establishment as human teratogen		Method of ascertainment as teratogen
		Year	Reference	
Alcohol	Rat	1973	(61)	Cluster of similar cases confirmed by epidemiological studies
Androgenic/progestogenic hormones	Rat	1953	(62)	Case reports, aided by similar findings in animals
Anticancer antimetabolites				
Aminopterin	Human	1956	(63)	Case reports
Fluorouracil	Mouse	1980	(64)	Case reports
Methotrexate	Rat	1968	(65)	Case reports
Cytarabine	Rat	1980	(66)	Case reports
Anticancer alkylating agents				
Busulfan	Rat	1960	(67)	Case reports
Chlorambucil	Mouse	1963	(68)	Case reports
Cyclophosphamide	Rat	1964	(69)	Case reports
Mechlorethamine	Rat	1974	(70)	Case reports
Anticonvulsants				
Hydantoins	Mouse	1975	(71)	Epidemiological studies
Diones	Human	1975	(72)	Cases noted as part of genetic evaluation
Valproate	Rat	1982	(73)	Epidemiological study
Antithyroid agents	Human	1940s-50s	(various)	Case reports, aided by similar findings in animals
DES	Rat	1970	(74)	Cluster of similar cases, con- firmed by case collection in Registry
Methylmercury	Human	1959	(75)	Epidemiological study
Thalidomide	Human	1961	(76, 77)	Cluster of similar cases
Lithium	Mouse	1973	(78)	Collection of cases via Registry
D-Penicillamine	Human	1971	(79)	Case reports
Streptomycin antibiotics	Human	1960s	(Various)	Case reports aided by similar findings in animals
Coumarin anticoagulants	Human	1968	(80)	Case reports
Vitamin A analogs	Rat	1983	(81)	Case reports

in mice. Second, the scientific consideration is that the species utilized in the assessment of teratogenicity should be that species which most closely resembles the human with respect to metabolism, pharmacokinetics, excretion, etc., and the rat undoubtedly would most likely be the species under study in this regard. Increasing emphasis on the role of pharmacokinetics is perhaps best exemplified by the suggestion of United Kingdom and Canadian regulatory agencies that it may be useful to compare the pharmacokinetics of a drug in nonpregnant and pregnant animals to determine the maternal-fetal distribution of the drug. A final consideration is that a "sensitive" species be used. Regulatory agencies of the U.S., Japan, and Europe have suggested that the spe-

cies and strain used should be "characterized for its response to teratogens," and as we shall note later, rats and rabbits are susceptible to most known teratogenic insults.

Identification of Human Teratogens

Recognition or identification of teratogens in the human is extremely tenuous for several reasons: therapeutic dosages or exposure levels are generally several orders of magnitude lower than doses purposefully given to animals to elicit malformations; pregnant women are (hopefully!) not usually given long courses of drug therapy nor a large number of drugs in this age of thera-

Table 3. Predictability of laboratory animal models for putative human teratogens.^a

Teratogen/group	Mouse	Rat	Rabbit	Hamster	Primate	Dog	Cat	Pig	Ferret	Guinea pig
Alcohol	+	+	-		+	+		+		+
Androgenic hormones ^b	+	+	+	+	+	+		+		+
Anticancer antimetabolites ^c	±	+	+	-	±	±	±	+		+
Anticancer alkylating agents ^d	+	+	+		+				+	
Anticonvulsants ^e	+	±	+	-	±	-	-			
Coumarin anticoagulants	-	-	-					-		
Antithyroid agents ^b	+	+	+							+
Progestogenic hormones ^b	+	±	±		-	+				+
DES ^b	+	+	-	±	+				+	
Methylmercury	+	+	-	+	-	-	+	-		
Thalidomide	±	±	+	±	+	±	±	±	+	-
Lithium	+	-	-		-			-		
D-Penicillamine		+		+						
Streptomycin antibiotics ^b	-	+	-							-
Vitamin A analogs	+	+	+	+	+	+		+		+

^aLegend: (+) teratogenic; (±) variably teratogenic; (-) not teratogenic.

^bDefects related to functional activity.

^cIncludes azauridine, aminopterin, fluorouracil, methotrexate and cytarabine.

^dIncludes busulfan, chlorambucil, cyclophosphamide, and mechlorethamine.

^eIncludes hydantoin and dione groups, and valproate.

peutic nihilism; the means of proving causation or even association in humans requires extensive analysis and a large number of controlled cases, etc. In addition, many chemicals which have demonstrated teratogenic properties in animals have no normal means of exposure to the human populace, and the human response has simply never been put to test.

While with one exception all putative teratogens in the human have been teratogenic in one or more laboratory animal species as well, unfortunately it has not been the case that discovery of teratogenic potential of a given chemical was made in animals prior to humans (Table 2). Of the 22 individual or groups of human teratogenic chemicals listed, eight were first identified as teratogens in the human. Included in the group are of course the notorious thalidomide, aminopterin, and methylmercury, all well known teratogens, perhaps publicized more widely because of their initial identification in the human species.

The method of detection of teratogens in the human remains primarily astute clinicians' reports of individual cases or, with several classic teratogens, e.g., thalidomide and diethylstilbestrol, through almost intuitive observation of clusters of similar cases. The detection of the latter chemicals was aided by the fact that the abnormalities observed in both examples were of such rarity as to direct attention towards their occurrence. Prior to the establishment of thalidomide as a causal agent, for instance, phocomelia or amelia, the defect it induced, occurred only very rarely (82); likewise, vaginal neoplasms had only been recorded in a few instances in the entire world medical literature prior to the causal association with diethylstilbestrol (83). Even so, sufficient numbers of cases are required to ensure recognition; solitary case reports do not demonstrate association, let alone establish causation. Detection of some of the remainder of human teratogens on the list has been much less fortuitous. Consider for instance,

that 15 years elapsed between the first recorded association of alcohol consumption and teratogenesis and acceptance in the scientific community that alcohol was the causal agent of a specific syndrome. Contrast this to the suspicion made regarding thalidomide in 1961 and its removal from the market almost worldwide within the course of less than one year.

The reliability of a particular animal study to predict the fate of a chemical when applied to humans is never fully known until sufficient epidemiological studies have shown how the human responds to the substance. Thus, the best evidence of an adverse human health effect may well be a properly conducted epidemiological study (84-87). However, this has not been the case: in only three instances—methylmercury, valproic acid, and the hydantoin anticonvulsants—have epidemiological studies as opposed to any other means of identification been the primary determinant of teratogenic potential.

Methods used to identify teratogenic hazards in human populations must, of course, depend on their ability to identify an exposed group and documentation of exposure (88). This is generally easiest for drugs, whose use is usually recorded; it is relatively easy for chemicals used socially for which individuals determine their own pattern of usage and document it fairly reliably; it is fairly difficult for occupational exposures, for which exposed individuals can usually be identified but for which the magnitude of exposure is usually difficult to estimate and exposure to single chemicals is uncommon, and is very difficult for environmental chemicals, for which both the distribution and magnitude of exposures are difficult to document.

Let us examine the process by which animal models can be used to aid in predicting the human response to teratogens: how the model reacts to known human teratogens and how it reacts or overreacts to agents not considered teratogens. In the former case, are the target sites the same?

Table 4. Predictability of animal models to concordant human malformations.

Teratogen	Reference malformation	Concordant	Nonconcordant
Alcohol	Craniofacial, limb, CV	Mouse, dog	Rat, guinea pig, pig
Androgenic/progestogenic hormones	Pseudohermaphroditism (♀)	Mouse, rat, guinea pig, hamster, rabbit, dog, pig, primate	
Anticancer antimetabolites			
Aminopterin	Skeletal	Rat	Dog, pig
Fluorouracil	Multiple visceral	Mouse, rat, guinea pig	Rabbit, primate
Methotrexate	Skeletal	Rabbit, cat	Mouse, rat, primate
Cytarabine	Limb, ear	Rat	Mouse
Anticancer alkylating agents			
Busulfan	Multiple visceral		Mouse, rat
Chlorambucil	Urogenital		Mouse, rat
Cyclophosphamide	Digits	Mouse, rat	Rabbit, primate
Mechlorethamine	Renal, limb, ear	Rat, rabbit, ferret	Mouse
Anticonvulsants			
Hydantoins	Facial, mental	Mouse	Rat, rabbit, primate
Diones	Facial, mental		Mouse, primate
Valproate	CNS		Mouse, rat, rabbit
Antithyroid agents	Hypothyroidism	Mouse, rat, guinea pig, rabbit	
DES	Uterine lesions	Mouse, rat, primate, ferret	
Methylmercury	Microcephaly, mental	Mouse, rat, cat	Hamster
Thalidomide	Limb	Rabbit, primate	Mouse, rat, hamster, dog, cat, pig, ferret
Lithium	CV		Mouse
D-Penicillamine	Skin lesion	Rat	Hamster
Streptomycin antibiotics	Inner ear	Rat	
Vitamin A analogs	CV, ear, brain	Rat, mouse, hamster, dog, primate	Rabbit, guinea pig, pig

Predictability of Animal Models to Human Teratogens

Chemicals or groups of chemicals that are universally recognized as being teratogenic to humans under certain conditions of exposure are tabulated in Table 3. The responses of the teratogens elicited in multiple laboratory species are also included: it is apparent that, with one exception (coumarin anticoagulants), every chemical or chemical group known to be teratogenic in humans is also teratogenic in one or more laboratory species. Thus positive animal teratology studies are at least suggestive of potential human response.

With respect to responses of individual species, it appears from this limited list that the ferret, guinea pig, mouse, and rat (in descending order) were the most predictive of the human response. However, in the first two species listed (ferret, guinea pig), testing was limited and may not be representative should more putative human teratogens be put to test in those species. That leaves the mouse and rat most predictive, successfully modeling the human reaction about 70% of the time. In this limited series, the rabbit, hamster, primate, canine, and swine all identified equally well (about

40–50% of the time) the human response. The cat was unacceptable in this regard, only identifying a single human teratogen of the four tested.

In the only other analysis of this type, the mouse was identified as the species most likely to yield a positive result among 38 chemicals from which there were reports of associated birth defects in humans (2).

Predictability of Concordant Malformations

It is considered by many that to be successful, animal models should mimic in the laboratory a similar or precise response to that of the human. Put another way, the limb malformations in humans induced by thalidomide were replicated in certain breeds of rabbits and in all but one primate species tested; these species are therefore considered better models than are those species in which malformations were induced by the drug, but which were not concordant, or the same type or pattern of reference malformation.

Concordant malformations to those induced by putative teratogens have been produced by one or more species of laboratory animals with but several excep-

tions (Table 4). Only several specific anticancer alkylating agents, several anticonvulsants, and lithium did not produce a similar pattern of defects in animals to those in humans. These data add credibility to use of animal models in teratology, since more than half of the known human carcinogens that have been adequately tested in animals produced tumors in one or more animal species at organ sites different from those produced in exposed humans (89).

Individual species responses, however, were less perfect, with no species having especially good predictive ability in type of teratogenic response. The mouse and rat produced the greatest number of concordant defects, but they also were responsible for the most nonconcordant responses as well.

Chemicals Not Teratogenic in Humans

Multispecies comparisons of animals exposed to the same chemical might be useful in assessing risk to humans, the rationale being that there might be clues to interspecies variability and sensitivity differences upon such comparison. Most comparisons that have been made represent direct animal-to-human extrapolation; animal-to-animal comparisons have been neglected in this respect. Many studies in the biological literature give results of testing numerous species for teratogenic potential of a given compound, therefore animal-to-animal comparisons can be made. One study that has been made addressing these relationships was reported recently by one of us (8).

A summary of the multispecies comparisons indicate that rabbits and monkeys offer greater predictability of possible human responses than do any of the other species (Table 5). Both species were responsive to all chemicals cited in only one-quarter of the cases. However, it should be stated that the primate in particular has been used for many of the cases to confirm the teratogenicity of chemicals, especially those already suspected of being teratogenic. Other commonly used species, including mouse and rat, reacted negatively about 50 to 60% of the time. Some other species, such as hamster, reacted positively to almost two-thirds of the chemicals examined, indicating little similarity to humans in actual teratogenic response.

In contrast to these results, rat and hamster responses were closest to those of humans in the nonteratogenic situations with respect to dose-response ("best response"). Mouse and pig also had close responses more than half the time, while rabbit and primate, the species most representative of the human response from the perspective of overall reaction, gave best responses only about 50% of the time, as did guinea pig.

Sensitivity comparisons indicated that rabbits and primates again were the most predictive in nonteratogenic situations, but this is to be expected since these species gave nonteratogenic responses more frequently than did the others. Cats were exquisitely sensitive, but the responses to the few chemicals studies may not

Table 5. Summary of species-to-species extrapolation.^a

Species	n ^a	NT/T,	Best % ^a response, % ^b	Sensitivity, % ^c	
				-	+
Rat	322	60	71	30	29
Mouse	289	53	59	37	33
Rabbit	270	74	50	50	40
Hamster	93	38	71	31	17
Primate	59	72	49	53	18
Dog	44	52	43	39	33
Guinea pig	24	48	50	33	23
Pig	21	62	62	0	0
Cat	8	25	0	100	83
Ferret	5	40	50	50	33

^an = Number of reports evaluated for particular species; NT/T = ratio of nonteratogenic reports of selected nonteratogenic agents in humans.

^bMost similar to humans in nonteratogenic response = highest nonteratogenic dosage.

^cLowest nonteratogenic dosage (-), lowest teratogenic dosage (+).

be representative of their full repertoire. When teratogenic responses were subjected to comparison, rabbit again was the leader, with mouse, rat, and dog not far behind.

Overall, analysis of data from this sort of animal-to-animal extrapolation, though admittedly crude, further indicated the wide variability of animal species in response to biological testing. The data do point out, in particular, however, that the use of rabbits and primates provides the greatest validity currently for predicting potential human teratogenicity.

Another FDA study addressing concordance of animal and human teratogenicity data came to a similar conclusion with respect to most predictive species (2). In the compilation reported, the monkey and the rabbit gave the best negative response with respect to human nonteratogens, providing correct (nonpositive) responses 80% and 70% of the time, respectively among some 165 chemicals studied. Concordance for the rat (50%), mouse (35%), and hamster (35%) was not as good.

There are a number of chemicals that are of importance because of occupational exposure which are known animal teratogens but are not known to be teratogenic in humans (Table 6). These chemicals are teratogenic in one or more species of laboratory animals; epidemiologic data are insufficient to determine their potential to adversely affect human development. Because of widespread human exposure to these chemicals in the absence of sufficient epidemiologic data coupled with their known teratogenicity in animals, exposure to these chemicals should be managed conservatively, and epidemiology studies should be considered a high priority.

Another group of chemicals (Table 7) of occupational and environmental importance have anecdotal reports in the literature of adverse reproductive or developmental outcomes. None of these chemicals are known to be teratogenic in humans. With but several exceptions, these chemicals are also nonteratogenic or only equivocally teratogenic in laboratory animals and would not be suspected as human teratogens based on the animal data.

Table 6. Chemicals teratogenic in laboratory and domestic animals which are not known to be teratogenic in humans.^{a,b}

Agent	Species				
	Rat	Mouse	Rabbit	Hamster	Other
Acrylonitrile	+	-		+	
Aminoacetonitrile	+		+	+	+ Sheep; ± monkey
Benomyl	+	+			
Bis-(2-ethylhexyl) phthalate	+	+	-		
N-Butyl methacrylate	+				
p-tert-Butyltoluene	+				
Cadmium	+	+	+	+	
Carbaryl	±	±	±	-	± Pig; + dog; + goat
Chlorfenvinphos	-		+	+	
Chloroform	±	+	-		
Chromium trioxide		+		+	
Di-n-butyl adipate	+				
Di-n-butyl phthalate	±	+			
Dichloroisobutylene	+				
Dieldrin	+	±	-	+	- Sheep; - dog
Di-2-ethylene adipate	+				
Di-2-ethylhexyl phthalate	±	+			
Diisobutyl adipate	+				
Dimethoate	±	-			+ Cat
Di-2-methoxyethyl phthalate	+				
Dimethylacetamide	+		-		
Dimethyl adipate	+				
Dimethyl phthalate	±				
Dimethyl sulfoxide	±	+	-	+	
2,4-Dinitrophenol	-	-	+		
Dipropyl adipate	+				
Endrin	+	±		+	
Ethyl acrylate	+		-		
Ethyl adipate	+				
Ethylene glycol monomethyl ether	±	+	+		
Ethylene glycol monoethyl ether	+	-	±		
Ethylene oxide	-	±	-		
Ethylene thiourea	+		-		
Ethyl methacrylate	+				
Ethyl methane sulfonate	+	+			
Ethyl nitrosourea	+	±	+	+	+ Pig
Ethyl phthalate	+				
Ferbam	+	-			
Heptachlor	+				
Hexachlorobutadiene	+				
Isobutyl methacrylate	+				
Isodecyl methacrylate	+				
Isopropyl methane sulfonate	+				
Linuron	+		-		
Malathion	±				
Methoxychlor	+				- Cow
N-Methyl acetamide	+				
Methyl chloride	-	+			
N-Methylformamide	+	+	-		
Methyl methanesulfonate	+	±			
N-Methylpyrrolidone	+	+			
Mono-2-ethylhexyl phthalate		+	-		
Monomethylacetamide			+		
Monomethylformamide			+		
Nickel carbonyl	+			+	
Nitrobenzene	+				
Nitrofen	+	+			
2-Nitropropane	+				
Paraoxon			+		
Pentachlorophenol	±	-		-	
Photomirex	+		-		
Piperonyl butoxide	-	-	+		
Polybrominated biphenyls	+	+			- Cow
Propachlor	+				
Propham		+			
Propineb	+				
Propoxur	+	-			

(continued)

Table 6. Continued

Agent	Species				
	Rat	Mouse	Rabbit	Hamster	Other
Pentachloronitrobenzene	-	+			
Sodium arsenate	+	+		+	
Sodium arsenite	+	+		-	
Sodium cyanide	+	+		+	
Sodium fluoride	±	±			+ Dog
Sodium trichloroacetate	+				
Strontium salts	+		+		
Succinonitrile				+	
Tetrachloroacetone		+	+		
2,3,7,8-Tetrachlorodibenzofuran		+			
Tetramethylurea	+	+	-		
Thiuram	-	±	-	+	
o-Toluenediamine	+		-		
Trichlorfon	+	+		+	+ Pig
Trichloropropionitrile	+				
Trichlorotoluene	+				
Trifluralin		+			

^a + Conflicting or equivocal reports.

^b See reviews by Schardein (1) and John et al. (90).

Table 7. Chemicals with anecdotal reports of human reproductive or developmental effects.^{a,b}

Agent	Species				Implicated human findings
	Rat	Mouse	Rabbit	Hamster	
Acetone					Birth defects
Benzene	-	±	-		Birth defects, chromosome aberrations
Boric acid	-	-			Birth defects, sperm abnormalities
Butiphos	-				Birth defects, stillbirths
Carbon disulfide	+		+		Decreased fertility, spontaneous abortions
Carbon monoxide	±	-	-		Stillbirth, birth defect
Chloroprene	±	+			Miscarriages
Dibromochloropropane	-				Infertility
Dimethylformamide	±	-	+		Miscarriages
Dinitrodipropyl sulfanilamide	-		-		Miscarriages, birth defects
Disulfiram	-			±	Birth defects
Ethylene dibromide	-	-			Decreased fertility
Formaldehyde	±	±			Spontaneous abortions
Hexachlorobenzene	±	+	-		Stillbirths, neonatal mortality
Lead	±	±	-	+	Infertility, spontaneous abortion, birth defects
Mercuric chloride	+				Spontaneous abortion
Methylene chloride	-	-			Birth defects
Methyl ethyl ketone	±				Birth defects
Methyl parathion	-	+			Birth defects
Polychlorinated biphenyls	-				Birth defects
Sodium selenite	-	-		-	Spontaneous abortion, birth defect
Styrene	±	±	-	-	Abortion
Toluene	-	+			Birth defects
Trichloroethylene	-	-	-		Birth defects
Vinyl chloride	-	-	-		Chromosome abnormalities, miscarriage, stillbirth, sperm abnormalities, birth defects
Xylene	-	±			Birth defects

^a ± Conflicting or equivocal reports.

^b See reviews by Schardein (1) and John et al. (83).

Predictability Based on Use of Nontraditional Endpoints

It is highly likely that analysis of endpoints other than structural malformation might prove to be valuable adjuncts for use in estimation of risk from animal models to the human. Other data emerging from developmental toxicity assessment, such as mortality, growth retardation, fertility rate, and/or functional impairment are

the most prominent parameters in this regard. To date, these have not been utilized to the fullest possible extent. Since obvious malformations are unreliable indicators of teratogenic activity in isolated initial screening tests, other parameters could be evaluated that often associate with teratogenicity, that occur more frequently and consistently and consequently are more readily analyzable (91). Palmer (92) pointed out some time ago that the low pregnancy rate, reduced litter

Table 8. Developmental toxicity endpoints.

Endpoint	Incidence rates, %				
	Mouse	Rat	Rabbit	Primate	Human ^a
Fertility		90			
Malformation	1-19	1-2	1-6	0.3-0.5	7 ^b
Abortion	—	—	1	8.7-14.4	10-30
Prenatal mortality	1-29	19	28		2.5-36.5 ^c
Neonatal mortality		0.5			12.9
Growth retardation					5-15

^aData largely from Sholtz (94).

^bOf livebirths.

^cFrom 20th week gestation on.

size, and poor viability observed in the early animal tests with thalidomide in rodents should have attested to the potential hazard of this chemical, even in the absence of teratogenicity. Combining several endpoints into risk assessment schemes has been recommended for other toxicities, especially mutagenesis (93). Background data for several of these endpoints are given in Table 8.

Discussion and Conclusion

Recognized human teratogens, except for coumarins, are also teratogenic in laboratory animals. However, many chemicals are teratogenic in laboratory animals that are not known to be teratogenic in humans. Whether this reflects lack of sensitivity of humans or lack of appropriate data in humans is unknown. Also, some chemicals might in fact be teratogenic in humans at some level of exposure but are managed such that there is no exposure of people to toxic levels.

There are sufficient epidemiologic data for many drugs to determine the human response and thus assess the predictability of animal data for human sensitivity. In contrast, there are generally insufficient epidemiologic data on most environmental and occupational chemicals to judge the predictability of animal data. Since animal data predict the effects of most chemicals where we have adequate human data, it is prudent to assume that animal data are also predictive of the human response to chemicals for which we have inadequate human data.

Among the species used for teratologic testing, the rat and mouse are the most successful in modeling the human reaction, but the rabbit is less likely than other species to give a false positive finding. No single species is clearly more predictive of the human response than others. Also, the organ systems or tissues affected in laboratory animals are not necessarily predictive of the type of response in humans. Lack of an effect in a particular organ in animals does not predict the absence of an effect in that organ in humans.

Assessment of the safety of drugs and other chemicals regarding teratogenic potential must take into account the following points. The greater the number of species with positive results, the greater the likelihood of an adverse effect in humans. All reproductive and developmental data should be used to predict safety, not just

data on malformations. A regulatory approach based on a number of similar considerations has been suggested for carcinogens (95) and seems equally applicable to developmental toxins. The relevancy of the route of exposure and existence of a dose-response relationship are important for all species. Data from any species must be used in the context of the total data base for the agent, including pharmacologic, disposition, and toxicologic data.

REFERENCES

1. Schardein, J. L. Chemically-Induced Birth Defects. Marcel Dekker, New York, in press.
2. Brown, N. A., and Fabro, S. The value of animal teratogenicity testing for predicting human risk. Clin. Obst. Gynecol. 26: 467-477 (1983).
3. Stern, L. In-vivo assessment of the teratogenic potential of drugs in man. Pharmacol. Therap. (Suppl. 1) #4: 10-18 (1982).
4. Wilson, J. G. Reproduction and teratogenesis: current methods and suggested improvements. J. Assoc. Off. Anal. Chemists 58: 657-667 (1975).
5. Khera, K. S. Evaluation of the cat for teratogenicity studies. Toxicol. Appl. Pharmacol. 37: 149-150 (1976).
6. Tuchmann-Duplessis, H. Selection of animal species for teratological drug testing. In: Methods in Prenatal Toxicology. Evaluation of Embryotoxic Effects in Experimental Animals (D. Neubert, H. J. Merker, and T. E. Kwasigroch, Eds.), Georg Thieme Publ., Stuttgart, 1977, pp. 25-34.
7. Tuchmann-Duplessis, H. The teratogenic risk. Progr. Clin. Biol. Res. 117: 245-258 (1983).
8. Schardein, J. L. Teratogenic risk assessment. Past, present, and future. In: Issues and Reviews in Teratology, Vol. 1 (H. Kalter, Ed.), Plenum Press, New York, 1983, pp. 181-214.
9. Buresh, J. J., and Urban, T. J. Palatal abnormalities induced by cortisone and corticosterone in the rat. J. Acad. Gen. Dent. 18: 34-37 (1970).
10. Buttar, H. S., Dupuis, I., and Khera, K. S. Fetotoxicity of trimethadione and paramethadione in rats. Toxicol. Appl. Pharmacol. 37: 126 (1976).
11. Gralla, E. J., and McIlhenny, H. M. Studies in pregnant rats, rabbits and monkeys with lithium carbonate. Toxicol. Appl. Pharmacol. 21: 428-433 (1972).
12. Kocher, W. Action and interaction of chemical and genetic factors in teratogenesis of the limb. Birth Defects 13: 1-18 (1977).
13. Kalter, H. Dose-response studies with genetically homogeneous lines of mice as a teratology testing and risk-assessment procedure. Teratology 24: 79-86 (1981).
14. Kalter, H. Experimental investigation of teratogenic action. Ann. N.Y. Acad. Sci. 123: 287-294 (1965).
15. Hansen, D. K., and Hodes, M. E. Metabolism of phenytoin in teratogenesis-susceptible and resistant strains of mice. Drug Metab. Dispos. 11: 21-24 (1983).

16. Webster, W. S., Walsh, D. A., Lipson, A. H., and McEwen, S. E. Teratogenesis after acute ethanol exposure in inbred and outbred mice. *Neurobehav. Toxicol.* 2: 227-234 (1980).
17. Giknis, M. L., and Damjanov, J. The teratogenic and embryotoxic effects of alcohol in four mouse strains. *Teratology* 21: 7 (1980).
18. Barlow, S. M., Morrison, P. J., and Sullivan, F. M. Effects of acute and chronic stress on plasma corticosterone levels in the pregnant and non-pregnant mouse. *J. Endocrinol.* 66: 93-99 (1975).
19. Hemm, R. D., Arslanoglou, L., and Pollock, J. J. Cleft palate following prenatal food restriction in mice: association with elevated maternal corticosteroids. *Teratology* 15: 243-248 (1977).
20. Szabo, K. T., and Brent, R. L. Species differences in experimental teratogenesis by tranquilizing agents. *Lancet* i: 565 (1974).
21. Barlow, S. M., Knight, A. F., and Sullivan, F. M. Diazepam-induced cleft palate in the mouse: the role of endogenous maternal corticosterone. *Teratology* 21: 149-155 (1980).
22. Ferm, V. H. The use of the golden hamster in experimental teratology. *Lab. Animal Care* 17: 452-462 (1979).
23. Shah, R. M. Usefulness of golden Syrian hamster in experimental teratology with particular reference to the induction of orofacial malformation. In: *Advances in the Study of Birth Defects. Vol. 2. Teratological Testing.* University Park Press, Baltimore, 1979, pp. 25-39.
24. Kromka, M., and Hoar, R. M. Use of guinea pigs in teratological investigations. *Teratology* 7: A21-22 (1973).
25. Hoar, R. M. The biology of the guinea pig. *Toxicology and teratology.* In: *The Biology of the Guinea Pig* (F. H. Wagner and P. J. Manning, Eds.), Academic Press, New York, 1976, pp. 269-280.
26. Stadler, J., Kessedjian, M. J., and Perraud, J. Use of the New Zealand white rabbit in teratology: incidence of spontaneous and drug-induced malformations. *Food Chem. Toxicol.* 21: 631-636 (1983).
27. Schwetz, B. A., Smith, F. A., and Staples, R. E. Teratogenic potential of ethanol in mice, rats and rabbits. *Teratology* 18: 385-392 (1978).
28. Matsuzawa, T., Nakata, M., Gotu, I., and Tsushima, M. Dietary deprivation indices, fetal loss and abortion in rabbits. *Toxicology* 22: 255-259 (1981).
29. Beck, F. The ferret as a teratological model. In: *New Approaches to the Evaluation of Abnormal Embryonic Development* (D. Neubert and H. J. Merker, Eds.), Thieme-Edition, Publishing Sciences Group, Stuttgart, 1975, pp. 8-20.
30. Beck, F., Schon, H., Mould, G., Scoidzinsho, P., Curry, S., and Grauwiler, J. Composition of the teratogenic effects of mustine hydrochloride in rats and ferrets. The value of the ferret as an experimental animal in teratology. *Teratology* 13: 157-160 (1976).
31. Gulamhusein, A. and Beck, F. The value of the ferret as an experimental animal in teratology. In: *Methods in Prenatal Toxicology. Evaluation of Embryotoxic Effects in Experimental Animals* (D. Neubert, H. J. Merker and T. C. Kwasigroch, Eds.), Georg Thieme, Stuttgart, 1977, pp. 44-51.
32. Haddad, R. F., and Hoar, R. M. Paper presented at Behavioral Teratology Society conference on the ferret as an alternative species in teratology and toxicology, Stanford, 1981.
33. Vorhees, C. V. Behavioral teratogenicity testing as a method of screening for hazards to human health: a methodological proposal. *Neurobehav. Toxicol.* 5: 469-474 (1983).
34. Earl, F. L., Miller, E., and Van Loon, E. J. Teratogenic research in beagle dogs and miniature swine. In: *Laboratory Animal Drug Testing, 5th Symposium, International Commission on Laboratory Animals, 1972* (A. Spiegel, Ed.), Fischer, Stuttgart, 1973, pp. 233-247.
35. Palludan, B. The value of the pig as an experimental animal in teratology. In: *Methods in Prenatal Toxicology. Evaluation of Embryotoxic Effects in Experimental Animals* (D. Neubert, H. J. Merker and T. E. Kwasigroch, Eds.), Georg Thieme, Stuttgart, 1977, pp. 35-43.
36. Mulvihill, J. J., and Priester, W. A. Congenital heart disease in dogs: epidemiologic similarities to man. *Teratology* 7: 73-78 (1973).
37. Esaki, K. The beagle dog in embryotoxicity tests. *Teratology* 18: 129-130 (1978).
38. Khara, K. S. Teratogenic effects of methylmercury in the cat: note on the use of this species as a model for teratogenicity studies. *Teratology* 8: 293-304 (1973).
39. Tanimura, T., and Shepard, T. H. The pigtailed macaque as a tool in experimental teratology. *Cong. Anom.* 10: 200 (1970).
40. Wilson, J. G. Use of rhesus monkeys in teratological studies. *Fed. Proc.* 30: 104-109 (1971).
41. Poswillo, D. E., Hamilton, W. J., and Sopher, D. The marmoset as an animal model for teratological research. *Nature* 239: 460-462 (1972).
42. Lister, R. E. Experimental teratology in primates. *Biochem. Soc. Trans.* 2: 695-699 (1974).
43. Bruggeman, S., and Grauwiler, J. The use of primates in teratological studies. *Stal. Sci. Tech. Anim. Lab.* 1: 243-248 (1976).
44. Siddall, R. A. The use of marmosets (*Callithrix jacchus*) in teratological and toxicological research. *Prim. Med.* 10: 215-224 (1978).
45. Hendrickx, A. G., and Binkerd, P. E. Primate teratology: selection of species and future use. In: *Advances in the Study of Birth Defects. Vol. 2, Teratologic Testing*, Univ. Park Press, Baltimore, 1979, pp. 1-23.
46. Scott, W. J., Wilson, J. G., Ritter, E. J., and Fradkin, R. Further studies on the distribution of teratogenic drugs in pregnant rats and rhesus monkeys. In: *Role of Pharmacokinetics in Prenatal and Perinatal Toxicology* (D. Neubert, H. J. Merker, H. Nau and J. Langman, Eds.), Georg Thieme, Stuttgart, 1978, pp. 499-506.
47. Wilson, J. G. Use of rhesus monkeys in teratological studies. *Fed. Proc.* 30: 104-109 (1972).
48. Froberg, H. An introduction to research in teratology. In: *Methods in Prenatal Toxicology. Evaluation of Embryotoxic Effects in Experimental Animals* (D. Neubert, H. J. Merker and T. E. Kwasigroch, Eds.), Georg Thieme, Stuttgart, 1977, pp. 1-13.
49. Omenn, G. S. A framework for reproductive risk assessment and surveillance. *Teratog. Carcinog. Mutag.* 4: 1-14 (1984).
50. Book, S. A. Scaling toxicity from laboratory animals to people. An example with nitrogen dioxide. *J. Toxicol. Environ. Health* 9: 719-726 (1982).
51. FDA. Guidelines for Reproduction Studies for Safety Evaluation of Drugs for Human Use. Drug Review Branch, Division of Toxicological Evaluation, Bureau of Science, Food and Drug Administration, Washington, DC, 1966.
52. FDA. Toxicological Principles for Safety Assessment of Direct Food Additives and Color Additives Used in Foods. Bureau of Foods, Food and Drug Administration, Washington, DC, 1982.
53. EPA. Pesticide Assessment Guidelines Subdivision F, Hazard Evaluation: Human and Domestic Animals. Office of Pesticide Programs, Environmental Protection Agency, 1982.
54. Health and Welfare, Canada. Guidelines for Pesticide Toxicology Data Requirements, Health Protection Branch, Ottawa, 1981.
55. Health and Welfare, Canada. Preclinical Toxicologic Guidelines. Health Protection Branch, Bureau of Human Prescription Drugs, Ottawa, 1981.
56. Japan Department of Health and Social Security. Notes for Guidance on Reproduction Studies. Medicines Act 1951 (MAL 2) Ref MLX 66, MAL 36, Department of Health and Social Security, 1974, 1976 (rev.).
57. Ministry of Health and Welfare, Japan. Guidelines of Toxicity Studies, Notification No. 118, Pharmaceutical Affairs Bureau, Yakugyo Jiko Co., Tokyo, 1984.
58. Ministry of Agriculture and Forestry, Japan. Toxicity and Residue Tests Necessary for Registration of Agricultural Chemicals In Japan. Pesticide Residue Section, Agricultural Inspection Station, MAJ, 1973.
59. OECD. Guidelines for Testing of Chemicals. Director of Information, OECD, Paris, France, 1981.
60. WHO. Guidelines for Evaluation of Drugs for Use in Man. World Health Organization Tech. Rept. Ser. No. 563, 1975.
61. Jones, K. L., Smith, D. W., and Ulleland, C. J. Pattern of malformation in offspring of chronic alcoholic mothers. *Lancet* i: 1267-1271 (1973).
62. Zander, J., and Muller, H. A. Uber die methylandrostendiolbehandlung wahrend einer Schwangerschaft. *Geburtshilfe Frauenheilkd.* 13: 216-222 (1953).

63. Meltzer, H. J. Congenital anomalies due to attempted abortion with 4-aminopteroylglutamic acid. *J. Am. Med. Assoc.* 161: 1253 (1956).
64. Stephens, J. D., Golbus, M. S., Miller, T. R., Wilber, R. R., and Epstein, C. J. Multiple congenital anomalies in a fetus exposed to 5-fluorouracil during the first trimester. *Am. J. Obstet. Gynecol.* 137: 747-748 (1980).
65. Milunsky, A., Graef, J. W., and Gaynor, M. F. Methotrexate-induced congenital malformations. *J. Pediatr.* 72: 790-795 (1968).
66. Wagner, V. M., Hill, J. S., Weaver, D., and Baehner, R. L. Congenital abnormalities in baby born to cytarabine treated mother. *Lancet* ii: 98-99 (1980).
67. Diamond, I., Anderson, M. M., and McCreadie, S. R. Transplacental transmission of busulfan (Myleran) in a mother with leukemia. Production of fetal malformation and cytomegaly. *Pediatrics* 25: 85-90 (1960).
68. Shotton, D., and Monie, I. Possible teratogenic effect of chlorambucil on a human fetus. *J. Am. Med. Assoc.* 186: 74-75 (1963).
69. Greenberg, L. H., and Tanaka, K. R. Congenital anomalies probably induced by cyclophosphamide. *J. Am. Med. Assoc.* 188: 423-426 (1964).
70. Garrett, M. J. Teratogenic effects of combination chemotherapy. *Ann. Int. Med.* 80: 667 (1974).
71. Hanson, J. W., and Smith, D. W. The fetal hydantoin syndrome. *J. Pediatr.* 87: 285-290 (1975).
72. Zackai, E. H., Mellman, W. J., Neiderer, B., and Hanson, J. W. The fetal trimethadione syndrome. *J. Pediatr.* 87: 280-284 (1975).
73. Robert, E. Valproic acid and spina bifida: a preliminary report — France. *Morbid. Mortal. Wkly. Rept.* 31: 565-566 (1982).
74. Herbst, A. L., and Scully, R. E. Adenocarcinoma of the vagina in adolescence. A report of seven cases including six clear cell carcinomas (so-called mesonephromas). *Cancer* 25: 745-757 (1970).
75. Kitamura, S., Hirano, Y., Noguchi, Y., Kojima, T., Kakita, T., and Kuwaki, H. The epidemiologic survey on Minamata disease (No. 2). *J. Kumamoto Med. Soc.* 33 (Suppl. 3): 569-571 (1959).
76. Lenz, W. Kindliche Missbildungen nach Medikament-Einnahme während der Gravidität? *Dtsch. Med. Wochenschr.* 86: 2555-2556 (1961).
77. McBride, W. G. Thalidomide and congenital abnormalities. *Lancet* ii: 1358 (1961).
78. Schou, M., Goldfield, M. D., Weinstein, M. R., and Villeneuve, A. Lithium and pregnancy. 1. Report from the register of lithium babies. *Brit. Med. J.* 2: 135-136 (1973).
79. Mjølnerod, O. K., Rasmussen, K., Dommerud, S. A., and Gjerdulsen, S. T. Congenital connective-tissue defect probably due to D-penicillamine treatment in pregnancy. *Lancet* i: 673-675 (1971).
80. Kerber, I. J., Warr, O. S., and Richardson, C. Pregnancy in a patient with a prosthetic mitral valve. Associated with a fetal anomaly attributed to warfarin sodium. *J. Am. Med. Assoc.* 203: 223-225 (1968).
81. Rosa, F. W. Teratogenicity of isotretinoin. *Lancet* ii: 513 (1983).
82. Warkany, J. *Congenital Malformations—Notes and Comments.* Year Book Medical Publ., Chicago, 1971.
83. Herbst, A. L., Ulfelder, H., and Poskanzer, D. C. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. *N. Engl. J. Med.* 284: 878-881 (1971).
84. Flynt, J. W. Techniques for assessing teratogenic effects. *Environ. Health Perspect.* 18: 117-123 (1976).
85. Schwartz, H. The relevance of animal models for predicting human safety. *Drug Cosmet. Ind.* 120: 34, 125 (1977).
86. Rall, D. P. Relevance of animal experiments to humans. *Environ. Health Perspect.* 32: 297-300 (1979).
87. Klingberg, M. A., and Papier, C. M. *Teratoepidemiology.* J. Biosoc. Sci. 11: 233-258 (1979).
88. Nisbet, I. C. T., and Karch, N. J. *Chemical Hazards to Human Reproduction.* Noyes Data Corp., Park Ridge, NJ, 1983.
89. *Fed. Register* 45 (No. 15): 74984-74988 (Jan. 22, 1980).
90. John, J. A., Wroblewski, D. J., and Schwetz, B. A. Teratogenicity of experimental and occupational exposure to industrial chemicals. In: *Issues and Reviews in Teratology*, Vol. 2 (H. Kalter, Ed.), Plenum Press, New York, 1984, pp. 267-324.
91. Palmer, A. K. Regulatory requirements for reproductive toxicology: theory and practice. In: *Developmental Toxicology* (C. A. Kimmel and J. Buelke-Sam, Eds.), Raven Press, New York, 1981, pp. 259-287.
92. Palmer, A. K. Assessment of current test procedures. *Environ. Health Perspect.* 18: 97-104 (1976).
93. Legator, M. S., and Harper, B. I. Animal-human studies: an integrated approach to identifying hazardous chemicals in the workplace. *Progr. Clin. Biol. Res.* 109: 181-202 (1982).
94. Sholtz, R., Goldstein, H., and Wallace, H. M. Incidence and impact of fetal and perinatal disease. In: *Prevention of Embryonic, Fetal, and Perinatal Disease* (R. L. Brent and M. I. Harris, Eds.), DHEW Publ., Washington, DC, 1976, pp. 1-18.
95. Squire, R. A. Ranking animal carcinogens: a proposed regulatory approach. *Science* 214: 877-880 (1981).